A Precisely Controlled Long-Acting Immunosuppression Platform Enables Prolonged Survival of Vascularized Composite Allografts
Lee, S.; Zor, F.; Kulahci, Y.; Joseph, J.; Karagoz, H.; Barooj, S.; Malik, G.; Park, D.; Luo, J. N.; Zhu, L.; Wang, A.; Chung, K.; Li, N.; Shah, P.; Agus, E.; Janarthanan, G.; Vijayavenkataraman, S.; Baby, H. M.; Snapper, O.; Chen, X.; Slaughter, K.; Dang, M.; Sam, E.; Gorantla, A.; Zhang, W.; Karp, J. M.; Joshi, N.; Gorantla, V.
Show abstract
Vascularized composite allotransplantation (VCA) restores complex tissue defects but demands lifelong systemic immunosuppression. Oral tacrolimus (TAC) is limited by a narrow therapeutic window, pharmacokinetic variability, adherence challenges, and toxicity. Local delivery could mitigate these issues, yet clinical translation has been hindered by burst release, short duration, and the inability to co-deliver agents. We developed PRECISE (Programmable, REtrievable, Controlled ImmunoSuppression Encapsulator), an injectable, in-situ-forming PLGA depot that achieves long-acting, tightly controlled TAC release via structure-guided co-formulation with drug-binding agents (DBAs). GRAS small molecules (e.g., EGCG, maltotriose) identified by in silico docking and in vitro screening suppressed burst and modulated solvent efflux. Notably, rapamycin (RAPA) served dually as an mTOR inhibitor and a TAC-binding excipient, enabling synchronized dual-agent delivery. PRECISE eliminated burst in vitro and produced coordinated TAC+RAPA release with clinically compatible injectability. In rats, monthly intragraft dosing maintained systemic TAC/RAPA within the therapeutic window ([~]5-10 ng/mL) for >300 days, prolonged hindlimb allograft survival, expanded Tregs, and induced donor-specific hyporesponsiveness. Surgical retrieval of the depot triggered rapid TAC decline, demonstrating reversibility. In a stringent, fully MHC-mismatched porcine VCA model, PRECISE maintained on-target drug levels and extended graft survival beyond 90 days with minimal rejection and preserved vascular integrity. PRECISE is, to our knowledge, the first retrievable, injectable platform to deliver long-acting, dual-agent immunosuppression with controlled kinetics, rapid attainment of therapeutic steady state, and sustained graft protection. Its modular, structure-guided design enables clinical translation across VCA and solid-organ transplantation, delivering precise, durable, and safer immunosuppression.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Intra-Lymph Node Crosslinking of Antigen-Bearing Polymers Enhances Humoral Immunity and Dendritic Cell Activation 94%
- 3D bioprinting of an implantable xeno-free vascularized human skin graft 93%
- Vitrification and rapid rewarming of precision-cut liver slices for pharmacological and biomedical research 92%
Similar papers in this journal
- A scalable device-less biomaterial approach for subcutaneous islet transplantation 94%
- Custom-engineered hydrogels for delivery of human iPSC-derived neurons into the injured cervical spinal cord 93%
- Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy 93%
Similar papers in this journal
- Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies 94%
- Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats 94%
- Sustained vaccine exposure elicits more rapid, consistent, and broad humoral immune responses to multivalent influenza vaccines 93%
Similar papers in this journal
- Transmembrane Stem Cell Factor Protein Therapeutics EnhanceRevascularization in Ischemia without Mast Cell Activation 94%
- A Continuously Oxygenated Macroencapsulation System Enables High-Density Packing and Delivery of Insulin-Secreting Cells 94%
- Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.